Ibrutinib treatment for first-line and relapsed / refractory chronic lymphocytic leukemia: final analysis of PCYC-1102 study


The safety and efficacy of Ibrutinib ( Imbruvica ), a once-daily Bruton's tyrosine kinase inhibitor, in chronic lymphocytic leukemia / small lymphocytic lymphoma ( CLL/SLL ) was demonstrated in this phase 1b/2 study.

Extended follow-up up to 8 years is described, representing the longest follow-up for single-agent Ibrutinib, or any BTK inhibitor, to date.

Phase 1b/2 PCYC-1102 and extension study PCYC-1103 included patients receiving single-agent Ibrutinib in first-line or relapsed / refractory CLL/SLL.

Overall response rate was 89%, with similar rates in first-line ( 87%; complete response, 35% ) and relapsed / refractory settings ( 89%; 10% ).

Estimated 7-year progression-free survival ( PFS ) rates were 83% in first-line and 34% in relapsed / refractory settings.

Forty-one patients had CLL progression ( n=11 with Richter's transformation ).

Median PFS was not reached with first-line Ibrutinib.

In relapsed/refractory CLL/SLL, median PFS was 52 months overall, 26 months in patients with chromosome 17p deletion, 51 months with 11q deletion, not reached with trisomy 12 or 13q deletion, and 88 months in patients without these cytogenetic abnormalities.

Estimated 7-year overall survival rates were 84% in first-line and 55% in relapsed / refractory settings.

Grade 3 or more adverse events in 15% or more of patients were hypertension ( 28% ), pneumonia ( 24% ), and neutropenia ( 18% ).
These grade greater than or equal to 3 adverse effects generally declined over time, except hypertension.

Adverse reactions leading to discontinuation in 2 or more patients were only observed in the relapsed / refractory setting ( sepsis, diarrhea, subdural hematoma, Richter's transformation ).

In conclusion, with up to 8 years of follow-up, sustained responses and long-term tolerability of single-agent Ibrutinib were observed with treatment of first-line or relapsed / refractory CLL/SLL, including high-risk CLL/SLL. ( Xagena )

Byrd JC et al, Clin Cancer Res 2020; Online ahead of print

XagenaMedicine_2020



Indietro

Altri articoli

Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...


There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...


In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...


The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...


The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...


The U.S. Food and Drug Administration ( FDA ) has approved Gallium 68 PSMA-11 ( Ga 68 PSMA-11 ), the...


The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...


The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...